Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



We’re running out of time to tackle COVID-19 vaccine hesitancy

The seeds of doubt are being sown before a vaccine has even been approved. It is time to prepare the public for what could be a significant hurdle for any COVID-19 vaccine.

Open access article

The Royal Pharmaceutical Society has made this article free to access in order to help healthcare professionals stay informed about an issue of national importance.

To learn more about coronavirus, please visit:

We're running out of time to tackle COVID 19 vaccine hesitancy


Vaccine hesitancy has been deemed one of the top threats to global health by the World Health Organization

Vaccination is one of the most cost-effective ways of avoiding disease and, in the case of COVID-19, finding a successful vaccine is widely seen as our only permanent exit strategy from the pandemic.

Many hurdles stand in the way of developing a successful vaccination programme against COVID-19. But, arguably, the most significant of these is “vaccine hesitancy”.

Vaccine hesitancy — the reluctance or refusal to vaccinate despite the availability of vaccines — has been deemed one of the top threats to global health by the World Health Organization.

In 1998, a discredited study in The Lancet, linking the measles-mumps-rubella (MMR) vaccine to autism, had a catastrophic impact on vaccination rates; uptake of the vaccine dropped from around 91% to 54%.

Although uptake recovered after the paper was retracted several years later, more than 20 years on, the effects are still being felt — coverage of the MMR vaccine fell for the fifth year in a row in 2018/2019.

In March 2019, Simon Stevens, the chief executive of NHS England, warned that vaccination deniers were gaining traction on social media and could be contributing to the decline in MMR uptake. And concerns are rising that the same issue could impede the success of potential COVID-19 vaccines.

Misinformation and “fake news” are already circulating about the vaccine, sowing seeds of doubt even before vaccines have completed clinical trials. Data from a panel study of more than 70,000 respondents carried out by University College London showed that 22% of people said they were unlikely to be vaccinated against COVID-19, with 30% of respondents having substantial beliefs that vaccines may cause future problems and around 15% believing vaccines do not work.

A smaller survey from the United States, published in the journal Vaccines, showed that although 68% of the 316 respondents were supportive of being vaccinated for COVID-19, concerns remained about side effects, sufficient vaccine testing and vaccine effectiveness.

Experts have suggested that herd immunity to COVID-19 will only be achieved when approximately 60% of the population is immune, either through naturally acquired immunity after infection, or a vaccination. Therefore, hesitancy around a COVID-19 vaccine needs to be addressed now, as a matter of urgency.

The issue of trust in vaccines is a complicated one. It often reflects more general trends in society, the values and beliefs that are distilled in childhood, and the personal experiences of the individual.

And there is little evidence on what works in those who are more vaccine hesitant. National publicity campaigns raise uptake, but there are doubts about whether they really reach those who are most resistant. Simply providing more information about a vaccine does not always address the underlying causes of vaccine hesitancy.

For example, the news that the government may use emergency powers to allow an unlicensed COVID-19 vaccine to be used in the UK led many to conflate the term “unlicensed” with “untested”, and when the Oxford University vaccine trial was paused it led to questions over transparency, despite the fact that pausing a trial is a routine part of vaccine development.

Interestingly, a recent paper in The Lancet suggested that confidence in the importance of vaccines — rather than in their safety or effectiveness — was most strongly linked with vaccine uptake. And one of the most powerful interventions is the interactions that people have socially and with healthcare professionals.

Of course, this includes pharmacists, who will be an important part of any national vaccination effort.

To support this, there must be regular monitoring of vaccine confidence levels to detect trends indicating a need for interventions to sustain confidence in the COVID-19 vaccine. We need to dedicate enough time to support those administering vaccines, to help them directly address concerns and explain why a vaccine is our best bet for overcoming this pandemic — ideally before a vaccine is released.

With the first COVID-19 vaccine promised by early 2021, maximising public trust in vaccination has to be of the highest priority. We need to start this work now, before it is too late.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208464

Readers' comments (1)

  • As a young child I was taken to measles, mumps and chicken pox parties to get them. My parents knew of people whose lives had been blighted by getting the diseases later in life. The advent of vaccination was welcomed then. Must a new generation suffer before their benefits are recognised again?

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmaceutical Statistics

    Pharmaceutical Statistics

    This book on basic statistics has been specifically written for pharmacy students.

    £33.00Buy now
  • Pharmacy in Public Health

    Pharmacy in Public Health

    Pharmacy in Public Health focuses on the important topics in public health relevant to all pharmacists.

    £33.00Buy now
  • Pharmacy Registration Assessment Questions

    Pharmacy Registration Assessment Questions

    Pharmacy Registration Assessment Questions features over 400 closed book and calculation questions. With the registration exam having gone through a complete transformation in 2016, this volume has been developed around the new General Pharmaceutical Council (GPhC) guidelines.

    £33.00Buy now
  • Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2 features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own. All questions are in line with current GPhC guidance, enabling you to prepare for the pharmaceutical pre-registration exam with confidence.

    £35.00Buy now
  • Pharmacy Registration Assessment Questions Package

    Pharmacy Registration Assessment Questions Package

    Pharmacy Registration Assessment Questions is a revision series featuring closed book and calculation questions. It can be used in conjunction with previous volumes or on its own to help you prepare for the GPHC exams.

    £80.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.